Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/16/2023 | Buy → Neutral | BTIG Research | |
| 1/5/2023 | $4.00 → $20.00 | Buy | BTIG Research |
| 6/23/2022 | $2.00 | Neutral | BofA Securities |
| 4/28/2022 | $5.50 | Hold | Berenberg |
| 1/12/2022 | $9.00 | Buy | Deutsche Bank |
| 12/7/2021 | $8.00 | Neutral | Citigroup |
| 12/2/2021 | $14.00 | Buy | Canaccord Genuity |
| 12/2/2021 | $9.00 | Hold | Jefferies |
Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company"), one of the world's fastest growing digital healthcare companies, announces that David Humphreys will be appointed as the Company's new Chief Financial Officer. Mr. Humphreys has been at Babylon for nearly two years in the role of Finance Director, with overall responsibility for building and scaling Babylon's finance function. Formerly, he was US-based as a Silicon Valley and New York Partner with PwC for over 20 years, working with Boards and leaders of fast-moving, rapid-growth companies including Tesla and Facebook to which he provided accounting consulting, transaction, IPO, M&A and auditing services to ensure complianc
SC 13D/A - Babylon Holdings Ltd (0001866390) (Subject)
SC 13G/A - Babylon Holdings Ltd (0001866390) (Subject)
SC 13G/A - Babylon Holdings Ltd (0001866390) (Subject)
BTIG Research downgraded Babylon from Buy to Neutral
BTIG Research reiterated coverage of Babylon with a rating of Buy and set a new price target of $20.00 from $4.00 previously
BofA Securities initiated coverage of Babylon with a rating of Neutral and set a new price target of $2.00
Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company") today announced its financial and operating results for the first quarter ended March 31, 2023. First Quarter Financial Results Comparison of the following financial results for the three months ended March 31, 2023, to the three months ended March 31, 2022: Total revenue was $311.1 million compared to $266.4 million, a 1.2x year-over-year increase of $44.7 million. This was primarily due to the growth in VBC revenue, which increased by 17% year-over-year to $287.5 million in Q1 2023. Net loss totaled $63.2 million, a (20.3)% Net loss margin compared to Net loss of $29.1 million, a (10.9)% Net loss margin in Q1 2022
Babylon (NYSE:BBLN) (the "Company") today announced it will host a conference call to review its first quarter financial results on Wednesday, May 10, 2023, at 8:00 AM Eastern Time. A press release announcing the results will be issued prior to the conference call on Wednesday, May 10, 2023. To participate in the live conference call and webcast, please dial (877) 407-7994 for U.S. participants, 0 800 756 3429 for U.K. participants or +1 215-268-9868 for international participants. Alternatively, you can visit the "News & Events" section of https://ir.babylonhealth.com to access the live webcast. On this page, you can also find a "Call me" link for instant telephone access to the event, w
Revenue grew 3.5x YoY, to $1.11 billion, exceeding guidance Cost of Care Delivery (COCD) Margin in the U.K. already profitable1, with U.S. Clinical services also expecting COCD profitability in early 2023 Key U.S. VBC contracts delivered profitable Medical Margins2 in their first year Monthly Adjusted EBITDA of $(16.3) million for Q4 2022 beating guidance of $(18) million Adjusted EBITDA profitability expected in mid-2024, significantly earlier than previous guidance Commercial VBC revenue substantially increased with recent launch of Ambetter digital-first service across 6 states Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company") today announced its financial an
4 - Babylon Holdings Ltd (0001866390) (Issuer)
4 - Babylon Holdings Ltd (0001866390) (Issuer)
4 - Babylon Holdings Ltd (0001866390) (Issuer)
8-K - Babylon Holdings Ltd (0001866390) (Filer)
8-K - Babylon Holdings Ltd (0001866390) (Filer)
NT 10-Q - Babylon Holdings Ltd (0001866390) (Filer)
- Reuters
Gainers Benitec Biopharma Inc. (NASDAQ:BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy. TRxADE HEALTH, Inc. (NASDAQ:MEDS) shares jumped 91.9% to $16.20. TRxADE HEALTH issued correction to press release announcing its anticipated combination with Superlatus, Inc. MoonLake Immunotherapeutics (NASDAQ:MLTX) gained 75% to $45.50 after the company's Phase 2 study for Nanobody sonelokimabint met its primary endpoint in hidradenitis suppurativa. INVO Bioscience, Inc. (NASDAQ:INVO) shares jumped 41% to $0.2327 after dropping 5% on Friday. iMedia Brands, Inc. (NASDAQ:IMBI) gained
Gainers TRxADE HEALTH, Inc. (NASDAQ:MEDS) shares surged 84.1% to $15.54 in pre-market trading after jumping over 15% on Friday. Superlatus, Inc. signed a binding letter of intent to be acquired by TRxADE HEALTH. Digital Media Solutions, Inc. (NYSE:DMS) shares gained 71.4% to $0.5750 in pre-market trading after gaining around 5% on Friday. Digital Media Solutions recently reported slightly worse-than-expected Q1 sales results. INVO Bioscience, Inc. (NASDAQ:INVO) shares rose 70.8% to $0.2819 in pre-market trading after dropping 5% on Friday. SQZ Biotechnologies Company (NYSE:SQZ) shares rose 40% to $0.56 in pre-market trading after dropping around 23% on Friday. Eco Wave Power Global AB
Babylon Holdings Limited (the "Company" or "Babylon") (NYSE:BBLN) previously announced in its June 23, 2023 press release that the Company has received a proposal from AlbaCore Capital LLP ("AlbaCore") and MindMaze Group SA ("MindMaze") pursuant to which core operating subsidiaries of the Company would be transferred to MindMaze (the "Proposed Transaction"). The closing of the Proposed Transaction is expected in July 2023 and is subject to agreed documentation, various conditions and appropriate approvals, if required. The Proposed Transaction will not provide for any payment to the Company's Class A ordinary shareholders or other equity instrument holders, as AlbaCore will be exercising ri
After a thorough exploration of strategic alternatives, Babylon Holdings Limited (NYSE:BBLN) (including its subsidiaries, "Babylon") is pleased to provide an update on the recapitalization transaction, previously announced on May 10, following receipt of a proposal from AlbaCore Capital LLP on behalf of certain of its affiliates ("AlbaCore") and MindMaze Group SA ("MindMaze"), and share that Babylon has selected the previously announced take private proposal from the options considered. The proposal strongly positions Babylon to accelerate its core mission – to make high quality healthcare more accessible and affordable by combining the most cutting-edge technology with the best medical ex
Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company") today announced its financial and operating results for the first quarter ended March 31, 2023. First Quarter Financial Results Comparison of the following financial results for the three months ended March 31, 2023, to the three months ended March 31, 2022: Total revenue was $311.1 million compared to $266.4 million, a 1.2x year-over-year increase of $44.7 million. This was primarily due to the growth in VBC revenue, which increased by 17% year-over-year to $287.5 million in Q1 2023. Net loss totaled $63.2 million, a (20.3)% Net loss margin compared to Net loss of $29.1 million, a (10.9)% Net loss margin in Q1 2022